TY - JOUR
T1 - Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling
AU - van Rooijen, Geeske
AU - van Rooijen, Maaike
AU - Maat, Arija
AU - Vermeulen, Jentien M.
AU - Meijer, Carin J.
AU - Ruhe, Henricus G.
AU - de Haan, Lieuwe
AU - Alizadeh, Behrooz Z.
AU - Bartels-Velthuis, Agna A.
AU - van Beveren, Nico J.
AU - Bruggeman, Richard
AU - Cahn, Wiepke
AU - Delespaul, Philippe
AU - Myin-Germeys, Inez
AU - Kahn, Rene S.
AU - Schirmbeck, Frederike
AU - Simons, Claudia J. P.
AU - van Amelsvoort, Therese
AU - van Haren, Neeltje E.
AU - van Os, Jim
AU - van Winkel, Ruud
AU - Genetic Risk and Outcome of Psychosis (GROUP) Investigators
N1 - Funding Information:
The infrastructure for the GROUP study is funded through the Geestkracht programme of the Dutch Health Research Council (Zon-Mw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag)and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal and Delta.)We are grateful for the generosity of time and effort by the patients, their families and healthy subjects. Furthermore we would like to thank all research personnel involved in the GROUP project, in particular: Joyce van Baaren, Erwin Veermans, Ger Driessen, Truda Driesen, Karin Pos, Erna van 't Hag, Jessica de Nijs, Atiqul Islam, Wendy Beuken and Debora Op 't Eijnde.
Funding Information:
The infrastructure for the GROUP study is funded through the Geestkracht programme of the Dutch Health Research Council (Zon-Mw, grant number 10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord. Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center The Hague. Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem. Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal and Delta.) We are grateful for the generosity of time and effort by the patients, their families and healthy subjects. Furthermore we would like to thank all research personnel involved in the GROUP project, in particular: Joyce van Baaren, Erwin Veermans, Ger Driessen, Truda Driesen, Karin Pos, Erna van 't Hag, Jessica de Nijs, Atiqul Islam, Wendy Beuken and Debora Op 't Eijnde.
Funding Information:
The infrastructure for the GROUP study is funded through the Geestkracht programme of the Dutch Health Research Council (Zon-Mw, grant number 10-000-1001 ), and matching funds from participating pharmaceutical companies ( Lundbeck , AstraZeneca , Eli Lilly , Janssen Cilag ) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest , Arkin , Dijk en Duin , GGZ Rivierduinen , Erasmus Medical Centre , GGZ Noord Holland Noord . Groningen: University Medical Center Groningen and the mental health institutions: Lentis , GGZ Friesland , GGZ Drenthe , Dimence , Mediant , GGNet Warnsveld , Yulius Dordrecht and Parnassia psycho-medical center The Hague . Maastricht: Maastricht University Medical Centre and the mental health institutions: GGZ Eindhoven en De Kempen , GGZ Breburg , GGZ Oost-Brabant , Vincent van Gogh voor Geestelijke Gezondheid , Mondriaan , Virenze riagg , Zuyderland GGZ , MET ggz , Universitair Centrum Sint-Jozef Kortenberg , CAPRI University of Antwerp , PC Ziekeren Sint-Truiden , PZ Sancta Maria Sint-Truiden , GGZ Overpelt , OPZ Rekem . Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal and Delta .)
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2019/6
Y1 - 2019/6
N2 - Patients diagnosed with schizophrenia often report a low quality of life (QoL). The purpose of this study was to investigate whether we could replicate a cross-sectional model by Alessandrini et al. (2016, n = 271) and whether this model predicts QoL later in life. This model showed strong associations between schizophrenia spectrum symptoms and depressive symptoms on QoL, but lacked follow-up assessment. This model was adapted in the current study and the robustness was investigated by using a longitudinal design in which the association between baseline variables (including IQ, depression, schizophrenia spectrum symptoms as well as social functioning) and QoL during 3-years of follow-up was investigated. We included patients with a non-affective psychotic disorder (n = 744) from a prospective naturalistic cohort-study. In the cross-sectional model, with good measure of fit, both depression as well as social functioning was associated with QoL (direct path coefficient -0.28 and 0.41, respectively). Additionally. the severity of schizophrenia spectrum symptoms was highly associated with social functioning (direct path coefficient -0.70). Importantly, the longitudinal model showed good measures of fit, which strengthens the validity of the initial model and highlights that depression prospectively affect QoL while schizophrenia spectrum symptoms prospectively influence QoL via social functioning. The negative, longitudinal impact of a depression on QoL highlights the need to focus on treatment of this co-morbidity. (C) 2019 Elsevier B.V. All rights reserved.
AB - Patients diagnosed with schizophrenia often report a low quality of life (QoL). The purpose of this study was to investigate whether we could replicate a cross-sectional model by Alessandrini et al. (2016, n = 271) and whether this model predicts QoL later in life. This model showed strong associations between schizophrenia spectrum symptoms and depressive symptoms on QoL, but lacked follow-up assessment. This model was adapted in the current study and the robustness was investigated by using a longitudinal design in which the association between baseline variables (including IQ, depression, schizophrenia spectrum symptoms as well as social functioning) and QoL during 3-years of follow-up was investigated. We included patients with a non-affective psychotic disorder (n = 744) from a prospective naturalistic cohort-study. In the cross-sectional model, with good measure of fit, both depression as well as social functioning was associated with QoL (direct path coefficient -0.28 and 0.41, respectively). Additionally. the severity of schizophrenia spectrum symptoms was highly associated with social functioning (direct path coefficient -0.70). Importantly, the longitudinal model showed good measures of fit, which strengthens the validity of the initial model and highlights that depression prospectively affect QoL while schizophrenia spectrum symptoms prospectively influence QoL via social functioning. The negative, longitudinal impact of a depression on QoL highlights the need to focus on treatment of this co-morbidity. (C) 2019 Elsevier B.V. All rights reserved.
KW - WHOQOL-BREF
KW - DETERMINANTS
KW - SCALE
KW - RELIABILITY
KW - REMISSION
U2 - 10.1016/j.schres.2019.04.011
DO - 10.1016/j.schres.2019.04.011
M3 - Article
C2 - 31047723
SN - 0920-9964
VL - 208
SP - 82
EP - 89
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -